Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;13(1):21-38.
doi: 10.1038/nrd4176.

Therapeutic opportunities of the IL-22-IL-22R1 system

Robert Sabat  1 , Wenjun Ouyang  2 , Kerstin Wolk  1
Affiliations
Review

Therapeutic opportunities of the IL-22-IL-22R1 system

Robert Sabat et al. Nat Rev Drug Discov. 2014 Jan.

Abstract

Interleukin-22 (IL-22) is a key effector molecule that is produced by activated T cells, including T helper 22 (TH22) cells, TH17 cells and TH1 cells, as well as subsets of innate lymphoid cells. Although IL-22 can act synergistically with IL-17 or tumour necrosis factor, some important functions of IL-22 are unique to this cytokine. Data obtained over the past few years indicate that the IL-22-IL-22 receptor subunit 1 (IL-22R1) system has a high potential clinical relevance in psoriasis, ulcerative colitis, graft-versus-host disease, certain infections and tumours, as well as in liver and pancreas damage. This Review highlights current knowledge of the biology of the IL-22-IL-22R1 system, its role in inflammation, tissue protection, regeneration and antimicrobial defence, as well as the positive and potentially negative consequences of its therapeutic modulation.

PubMed Disclaimer

References

    1. FEBS Lett. 2008 Sep 3;582(20):2985-92 - PubMed
    1. Mucosal Immunol. 2013 Jan;6(1):69-82 - PubMed
    1. J Clin Invest. 2008 Feb;118(2):597-607 - PubMed
    1. Mol Cell Biochem. 2012 Oct;369(1-2):255-66 - PubMed
    1. N Engl J Med. 2012 Jan 12;366(2):158-64 - PubMed

MeSH terms